Literature DB >> 22371106

Prevention. Aspirin in primary prevention--good news and bad news.

Charles H Hennekens1, Colin Baigent.   

Abstract

The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22371106     DOI： 10.1038/nrcardio.2012.26

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  8 in total

1.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

2.  Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis.

Authors:  Charles H Hennekens; Danielle Hollar; Colin Baigent
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2006-01

3.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

4.  Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

5.  Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE).

Authors:  Mark Nelson; Christopher Reid; Lawrence Beilin; Geoffrey Donnan; Colin Johnston; Henry Krum; Elsdon Storey; Andrew Tonkin; John McNeil
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.

Authors:  Sreenivasa Rao Kondapally Seshasai; Shanelle Wijesuriya; Rupa Sivakumaran; Sarah Nethercott; Sebhat Erqou; Naveed Sattar; Kausik K Ray
Journal:  Arch Intern Med       Date:  2012-01-09

7.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

8.  Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins.

Authors:  Giorgia De Berardis; Michele Sacco; Virgilio Evangelista; Alessandro Filippi; Carlo B Giorda; Gianni Tognoni; Umberto Valentini; Antonio Nicolucci
Journal:  Trials       Date:  2007-08-28       Impact factor: 2.279
  8 in total
  2 in total

1.  Prevention: Aspirin in primary prevention needs individual judgements.

Authors:  Charles H Hennekens; David L DeMets
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

2.  Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not age.

Authors:  Kyungmann Kim; Charles H Hennekens; Lisa Martinez; J Michael Gaziano; Marc A Pfeffer; Bianca Biglione; Alexander Gitin; Jeanne Bell McCabe; Thomas D Cook; David L DeMets; Sarah K Wood
Journal:  Fam Med Community Health       Date:  2021-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.